ClinicalTrials.gov
public full text
Public Domain
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis. This is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, with an 8 week "pre post" open label extension in all 30 patients where they will receive empagliflozin daily.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Efficacy of Empagliflozin in Hemodialysis#127789
- Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients#123658
- Inflammation and Overweight in Peritoneal Dialysis: Is There an Association?#385545
- e-STEPS: Endotoxin-Associated Sterile Peritonitis Observational Study#893534
- Theranova vs High-flux HD Comparison#1060630
Record · ID 1378503
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive